Recombinant human β-defensin 2 delivery improves smoking-induced lung neutrophilia and bacterial exacerbation
- 1 July 2022
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 323 (1) , L37-L47
Abstract
Treatment of the cigarette smoke-associated lung diseases, such as chronic obstructive pulmonary disease (COPD), has largely focused on broad-spectrum anti-inflammatory therapies. However, these therapies, such as high-dose inhaled corticosteroids, enhance patient susceptibility to lung infection and exacerbation. Our objective was to assess whether the cationic host defense peptide, human β-defensin 2 (hBD-2), can simultaneously reduce pulmonary inflammation in cigarette smoke-exposed mice while maintaining immune competence during bacterial exacerbation. Mice were exposed to cigarette smoke acutely (4 days) or chronically (5 days/wk for 7 wk) and administered hBD-2 intranasally or by gavage. In a separate model of acute exacerbation, chronically exposed mice treated with hBD-2 were infected with nontypeable Haemophilus influenzae before euthanasia. In the acute exposure model, cigarette smoke-associated pulmonary neutrophilia was significantly blunted by both local and systemic hBD-2 administration. Similarly, chronically exposed mice administered hBD-2 therapeutically exhibited reduced pulmonary neutrophil infiltration and downregulated proinflammatory signaling in the lungs compared with vehicle-treated mice. Finally, in a model of acute bacterial exacerbation, hBD-2 administration effectively limited neutrophil infiltration in the lungs while markedly reducing pulmonary bacterial load. This study shows that hBD-2 treatment can significantly attenuate lung neutrophilia induced by cigarette smoke exposure while preserving immune competence and promoting an appropriate host-defense response to bacterial stimuli.Keywords
Funding Information
- Novo Nordisk Foundation (NNF17OC0026698)
- Lundbeck Foundation (R232-2016-2425)
This publication has 34 references indexed in Scilit:
- A new short-term mouse model of chronic obstructive pulmonary disease identifies a role for mast cell tryptase in pathogenesisJournal of Allergy and Clinical Immunology, 2013
- In vitro bactericidal activity of human β-defensin 2 against nosocomial strainsPeptides, 2010
- Infection as a comorbidity of COPDEuropean Respiratory Journal, 2010
- COPD exacerbations: defining their cause and preventionThe Lancet, 2007
- Antimicrobial Peptides Human β-Defensins Stimulate Epidermal Keratinocyte Migration, Proliferation and Production of Proinflammatory Cytokines and ChemokinesJournal of Investigative Dermatology, 2007
- Human β‐defensin‐2 functions as a chemotactic agent for tumour necrosis factor‐α‐treated human neutrophilsImmunology, 2004
- The Structure of Human Macrophage Inflammatory Protein-3α/CCL20Journal of Biological Chemistry, 2002
- Susceptibility of Nontypeable Haemophilus influenzae to Human β-Defensins Is Influenced by Lipooligosaccharide AcylationInfection and Immunity, 2002
- Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils.Thorax, 1996
- Oral vs Inhaled Asthma TherapyDrugs, 1996